Journal article
Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease
Abstract
BACKGROUND: Randomized clinical trials have shown that semaglutide is associated with a clinically relevant reduction in body weight and a lower risk of adverse cardiovascular events in those who are overweight or obese with a history of cardiovascular disease but no diabetes. The objective of this study was to assess the cost-effectiveness of semaglutide for this indication.
METHODS: A decision analytic Markov model was used to compare the …
Authors
Rennert-May E; Manns B; Clement F; Spackman E; Collister D; Sumner G; Leal J; Miller RJH; Chew DS
Journal
Canadian Journal of Cardiology, Vol. 41, No. 1, pp. 128–136
Publisher
Elsevier
Publication Date
January 2025
DOI
10.1016/j.cjca.2024.09.025
ISSN
0828-282X